Carregant...
Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas
There is a pressing need for more effective therapies to treat patients with T-cell lymphomas (TCLs), including first-line approaches that increase the response rate to cyclophosphamide, adriamycin, vincristine, and prednisone (CHOP) chemotherapy. We characterized the mitochondrial apoptosis pathway...
Guardat en:
| Publicat a: | Blood |
|---|---|
| Autors principals: | , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
American Society of Hematology
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6367646/ https://ncbi.nlm.nih.gov/pubmed/30498064 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2018-07-865527 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|